Osamu Tanaka1, Masahiko Oguchi2, Takayoshi Iida1, Senji Kasahara3, Hideko Goto3, Takeshi Takahashi3. 1. Department of Radiation Oncology, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu 500-8513, Japan. 2. Department of Radiation Oncology, Cancer Institute Hospital, 3-8-31 Koto Ariake, Tokyo 135-8550, Japan. 3. Department of Hematology, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu 500-8513, Japan.
Abstract
AIM: To determine the efficacy of low-dose palliative radiotherapy in patients with refractory aggressive lymphoma. BACKGROUND: There are few reports on the administration of palliative radiotherapy to patients with aggressive lymphoma. MATERIALS AND METHODS: The present study included 11 patients with 30 sites of aggressive lymphoma (diffuse large cell lymphoma, n = 7; mantle cell lymphoma, n = 2; follicular large cell lymphoma, n = 1; and peripheral T cell lymphoma, n = 1). The patients received local palliative radiotherapy after receiving a median of 4 chemotherapy regimens. The radiotherapy doses administered to the 30 sites were as follows: 8 Gy, single fraction (n = 27); 6 Gy, single fraction (n = 1); 4 Gy, single fraction (n = 1); and 4 Gy, 2 fractions (n = 1). RESULTS: The complete response rate was 45% (5/11); the partial response rate was 36% (4/11). Toxicity occurred at one irradiated site (the mandibular), which showed temporal acute gingivitis; however, medication was not required. Retreatment was required for 3 sites on the head (parotid, face and mandible) due to persistent discomfort. None of the other sites (27/30) required retreatment. A patient with refractory DLBCL underwent radiotherapy (4 Gy, single fraction) for hepatic hilar lymph node involvement but did not recover from jaundice and died of DLBCL. CONCLUSIONS: Eight Gray single fraction radiotherapy was one of meaningful options for the treatment of refractory aggressive lymphoma in terms of its efficacy and the incidence of adverse events. The use of 8 Gy single fraction radiotherapy is therefore recommended for achieving local control in patients with refractory aggressive lymphoma.
AIM: To determine the efficacy of low-dose palliative radiotherapy in patients with refractory aggressive lymphoma. BACKGROUND: There are few reports on the administration of palliative radiotherapy to patients with aggressive lymphoma. MATERIALS AND METHODS: The present study included 11 patients with 30 sites of aggressive lymphoma (diffuse large cell lymphoma, n = 7; mantle cell lymphoma, n = 2; follicular large cell lymphoma, n = 1; and peripheral T cell lymphoma, n = 1). The patients received local palliative radiotherapy after receiving a median of 4 chemotherapy regimens. The radiotherapy doses administered to the 30 sites were as follows: 8 Gy, single fraction (n = 27); 6 Gy, single fraction (n = 1); 4 Gy, single fraction (n = 1); and 4 Gy, 2 fractions (n = 1). RESULTS: The complete response rate was 45% (5/11); the partial response rate was 36% (4/11). Toxicity occurred at one irradiated site (the mandibular), which showed temporal acute gingivitis; however, medication was not required. Retreatment was required for 3 sites on the head (parotid, face and mandible) due to persistent discomfort. None of the other sites (27/30) required retreatment. A patient with refractory DLBCL underwent radiotherapy (4 Gy, single fraction) for hepatic hilar lymph node involvement but did not recover from jaundice and died of DLBCL. CONCLUSIONS: Eight Gray single fraction radiotherapy was one of meaningful options for the treatment of refractory aggressive lymphoma in terms of its efficacy and the incidence of adverse events. The use of 8 Gy single fraction radiotherapy is therefore recommended for achieving local control in patients with refractory aggressive lymphoma.
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Lisa Lowry; Paul Smith; Wendi Qian; Stephen Falk; Kim Benstead; Tim Illidge; David Linch; Martin Robinson; Andrew Jack; Peter Hoskin Journal: Radiother Oncol Date: 2011-06-12 Impact factor: 6.280
Authors: Elisa K Chan; Sharon Fung; Mary Gospodarowicz; David Hodgson; Woodrow Wells; Alexander Sun; Melania Pintile; Richard W Tsang Journal: Int J Radiat Oncol Biol Phys Date: 2010-12-16 Impact factor: 7.038
Authors: R L M Haas; Ph Poortmans; D de Jong; M Verheij; M van der Hulst; J P de Boer; H Bartelink Journal: Eur J Cancer Date: 2005-08 Impact factor: 9.162
Authors: R L M Haas; Ph Poortmans; D de Jong; B M P Aleman; L G H Dewit; M Verheij; A A M Hart; M H J van Oers; M van der Hulst; J W Baars; H Bartelink Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Monica Mead; Henrik Cederleuf; Maja Björklund; Xiaoyan Wang; Thomas Relander; Mats Jerkeman; Daria Gaut; Sarah Larson; Fredrik Ellin Journal: Blood Adv Date: 2022-04-12